DRNAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...

Stats
本日の出来高	5.54M
平均出来高	3.03M
時価総額	0.00
EPS	$-0.220 ( 2021-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.989 (2.59%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-28	Koppel Adam	Sell	3 080 237	Common Stock
2021-12-28	Koppel Adam	Sell	3 333	Restricted Stock Units
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 12 087 \| Sell: 8 528 928

ボリューム相関

長: 0.55 (weak)

短: 0.93 (very strong)

Signal:(82.281) Expect same movement, but be aware

Dicerna Pharmaceuticals 相関

10 最も正の相関
ORTX	0.976
ASLN	0.972
ADMS	0.97
CSII	0.969
GRBK	0.962
WPRT	0.96
UNCY	0.959
NERV	0.959
NATI	0.958
NNOX	0.956

10 最も負の相関
CPTN	-0.96
AADI	-0.958
CARA	-0.957
STIM	-0.956
PRAA	-0.955
BRKL	-0.953
VEON	-0.948
PEBK	-0.947
TCPC	-0.947
MDRX	-0.946

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dicerna Pharmaceuticals 相関 - 通貨/商品

0.21
( neutral )

0.70
( moderate )

0.36
( neutral )

0.60
( weak )

-0.69
( moderate negative )

-0.24
( neutral )

Dicerna Pharmaceuticals 財務諸表

Annual	2020
収益:	$164.31M
総利益:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2020
収益:	$164.31M
総利益:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2019
収益:	$23.90M
総利益:	$0.00 (0.00 %)
EPS:	$-1.760

FY	2018
収益:	$6.18M
総利益:	$0.00 (0.00 %)
EPS:	$-1.600

Financial Reports:

No articles found.

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.